Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trial.
Priscilla A HollanderWendy L CarofanoRaymond L H LamGregory T GolmRoy EldorMichael F CrutchlowMichael C MarcosMarc S RendellPhilip D HomeBaptist GallwitzJulio RosenstockPublished in: Diabetes, obesity & metabolism (2018)
Mk-Gla and Sa-Gla demonstrated similar efficacy and safety over 24 weeks of treatment in people with T2DM.